Welcome to our dedicated page for MIRA Pharmaceuticals news (Ticker: $MIRA), a resource for investors and traders seeking the latest updates and insights on MIRA Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MIRA Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MIRA Pharmaceuticals's position in the market.
Rhea-AI Summary
MIRA Pharmaceuticals, Inc. shares updates on the pre-clinical studies of Ketamir-2, a potential treatment for major mental health disorders. Ketamir-2, a novel oral ketamine analog, shows promising results for treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. The compound demonstrates excellent stability in blood, safe metabolism, and optimal protein binding. The company aims to file an IND with the FDA by year-end for human testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
-
Rhea-AI Summary
Dr. Itzchak Angel, a renowned pharmaceutical executive with over 40 years of experience, joins MIRA Pharmaceuticals as the new Chief Scientific Advisor. His expertise in drug development and regulatory approval is expected to accelerate MIRA's research and development pipeline, focusing on novel treatments for neurologic and neuropsychiatric disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
-
Rhea-AI Summary
MIRA Pharmaceuticals, Inc. announced a research collaboration with Pharmaseed to conduct pre-clinical studies on the use of Ketamir for patients with Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). The studies aim to investigate the antidepressant properties of Ketamir and position it for an initial IND application in 2024. Ketamir is designed to address the challenges presented by MDD and PTSD, offering administration ease and aiming for fewer side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.02%
Tags
Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has released new data from artificial intelligence (AI) simulations that show significant potential advantages of MIRA1a over plant-based medical marijuana in treating anxiety, appetite, and cognition. The simulations, conducted in collaboration with InSilicoTrials, indicate MIRA1a's potential as a superior anti-anxiety treatment with increased cognition and without the appetite increase associated with THC. MIRA1a's predicted ability to initiate a response at three pivotal brain receptors, as well as its unique properties and potential as an intervention for neurological disorders, position it as a promising development in neuropharmacological therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
-
Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced new data showing Ketamir-2's potential to reshape the landscape of depression treatment. The oral bioavailability of Ketamir-2 is predicted to be around 80%, with projections of annual sales reaching $3 billion by 2035, and estimates rising to up to $7.8 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
-
Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (MIRA) will host a shareholder update call on December 5, 2023, to discuss its exclusive licensing agreement for Ketamir-2, a novel oral ketamine analog for depressive disorder treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (MIRA) revealed groundbreaking insights into the cognitively enhancing effects of MIRA1a in normal mice during a presentation at the University of Louisville. Key findings include the unprecedented cognitive boost of MIRA1a, showcasing its potential in elevating cognitive abilities beyond normal thresholds. Dr. Adam Kaplin's research proposes a revolutionary approach to cognitive impairment treatment, positioning MIRA Pharmaceuticals as a trailblazer in the evolving landscape of psychotropic drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
-
News
Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced a partnership with MIRALOGX, LLC to develop and commercialize Ketamir-2, a novel oral ketamine analog for refractory depression and depression with suicidal thoughts. Ketamir-2 aims to provide ultra-rapid antidepressant effects and is not classified as a controlled substance by the DEA. Dr. Adam Kaplin, an esteemed expert in ketamine research, will lead the development of Ketamir-2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.06%
Tags
-
Rhea-AI Summary
MIRA Pharmaceuticals presents MIRA1a as a potential alternative to THC with unique properties and fewer side effects at the Cannabinoid Derived Drug Development Summit. Pre-clinical studies show that MIRA1a enhances cognitive performance and diminishes anxiety. The CEO of MIRA Pharmaceuticals highlights the unwanted side effects of marijuana as a reason for seeking alternatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.8%
Tags
Rhea-AI Summary
MIRA Pharmaceuticals announces strategic partnership with MZ Group to enhance visibility and potential of drug candidate MIRA1a. MIRA1a has shown therapeutic benefits in treating anxiety, cognitive decline, and neuropathic pain without the side effects of marijuana. The partnership aims to expand MIRA's presence in key markets through investor relations and financial communications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
MIRA Pharmaceuticals, Inc.
Nasdaq:MIRA
MIRA Rankings
MIRA Stock Data
11.23M
9.08M
29.05%
0.91%
0.39%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
MIAMI